---
title: Human Herpesvirus-6 Reactivation and Disease Are Infrequent in Chimeric Antigen
  Receptor T-cell Therapy Recipients
date: '2024-04-18'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38635788/?utm_source=curl&utm_medium=rss&utm_campaign=journals&utm_content=7603509&fc=None&ff=20240419180729&v=2.18.0.post9+e462414
source: Blood
description: Human herpesvirus-6B (HHV-6B) reactivation and disease are increasingly
  reported after CAR-T-cell therapy (CARTx). HHV-6 reactivation in the CAR-T-cell
  product was recently reported, raising questions about product and patient management.
  Due to overlapping manifestations with immune effector cell-associated neurotoxicity
  syndrome, diagnosing HHV-6B encephalitis is challenging. We provide two lines of
  evidence assessing the incidence and outcomes of HHV-6B after CARTx. First, in a
  ...
disable_comments: true
---
Human herpesvirus-6B (HHV-6B) reactivation and disease are increasingly reported after CAR-T-cell therapy (CARTx). HHV-6 reactivation in the CAR-T-cell product was recently reported, raising questions about product and patient management. Due to overlapping manifestations with immune effector cell-associated neurotoxicity syndrome, diagnosing HHV-6B encephalitis is challenging. We provide two lines of evidence assessing the incidence and outcomes of HHV-6B after CARTx. First, in a ...